The Alexandria Center for Advanced Technologies at The Woodlands is open for business. Rendering courtesy of Alexandria Real Estate Equities

A new innovation hub mega campus has opened in The Woodlands.

The Alexandria Center for Advanced Technologies at The Woodlands comes courtesy of California-based Alexandria Real Estate Equities Inc. The campus is home to the first purpose-built, cost-effective Class A laboratory infrastructure in the Houston suburb.

The campus takes advantage of Alexandria’s cluster model, which is informed by the cluster theory of business created by Harvard Business School’s Michael E. Porter. The belief behind the cluster is that there are four critical drivers necessary to creating a thriving business cluster: location, innovation, talent and capital. With nearly three decades of creating such STEM ecosystems, Alexandria is well positioned to grow something important in The Woodlands.

The campus’ first building is a 123,392-square-foot, LEED Gold Core and Shell, and Fitwel-certified redevelopment project. One of the initial tenants in that building is Nurix Therapeutics, a San Francisco-based clinical-stage biopharmaceutical company.

“We have had an outstanding strategic relationship with Alexandria since 2014 and approached them to support our expansion to Texas,” Arthur T. Sands, MD, PhD, president and chief executive officer of Nurix said in a press release. “The Woodlands offers us a business-friendly, entrepreneurial environment that is critical to our growth. Alexandria’s thoughtfully designed new campus provides us with state-of-the-art laboratory space and dynamic amenities that are key to helping us attract and retain top talent as we work to change the future of medicine through an exciting new modality of treating disease: targeted protein modulation.”

Nurix’s focus is treating cancer and other challenging diseases using protein modulation. Its expansion to the Houston area will help the company to build both proprietary and partnered programs in oncology as well as autoimmune and inflammatory diseases.

“Our efforts in The Woodlands are much like when we entered New York City, where commercial life science was very limited before we opened our flagship Alexandria Center for Life Science – NYC in 2010,” Joel S. Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments, says in a news release. "We are similarly committed to developing a commercial life science presence in The Woodlands.

"Steve Jobs once said, ‘the biggest innovations of the twenty-first century will be at the intersection of biology and technology,’ and his prediction has come to fruition," Marcus continues. "Here in The Woodlands, this important convergence will drive opportunities to accelerate the development of new medicines to benefit patients."

Care for a round of pickleball with a colleague? The Alexandria Center for Advanced Technologies campus is replete with appealing with amenities. They indeed include onsite pickleball courts, but also modern conference and event space; an large, welcoming courtyard and event lawn; and a wellness and fitness center so innovators can keep their bodies as healthy as their minds.

With the objective of further driving this STEM ecosystem, the company is also bringing the Alexandria Seed Capital Platform to The Woodlands. The nationwide platform unites leaders from across the life science community to catalyze early-stage investment in life science companies. If Alexandria’s goals come to fruition, more medical companies may soon be heading to Houston’s ‘burbs.

The Alexandria Center for Advanced Technologies at The Woodlands

Image courtesy of Alexandria Real Estate Equities

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.